Celldex Therapeutics (CLDX)
(Delayed Data from NSDQ)
$41.21 USD
-1.00 (-2.37%)
Updated May 8, 2024 04:00 PM ET
After-Market: $41.44 +0.23 (0.56%) 5:12 PM ET
2-Buy of 5 2
F Value F Growth D Momentum F VGM
Industry / Sector Report
Industry : Medical - Biomedical and Genetics
Zacks Industry Rank
Top 36% (90 out of 251)Zacks Sector Rank
Top 25% (4 out of 16)Recommendations and Estimates
Company | Industry | SP500 | |
---|---|---|---|
Average Recommendation (1=Buy, 5=Sell) | 1.25 | 1.35 | 9.99 |
Current Quarter Estimate | -0.68 | 7.43 | 57.00 |
Year Ago Quarter Estimate | -0.65 | 0.12 | 52.54 |
Next Quarter Estimate | -0.73 | 7.81 | 61.00 |
Next Year Estimate | -3.36 | 37.76 | 270.00 |
Growth Rates
Company | Industry | SP500 | |
---|---|---|---|
This Year | -7.14 | 13.20 | 15.67 |
Next Year | -17.89 | 8.30 | 9.31 |
Last 5 Years | NA | 1.00 | 8.10 |
Next 5 Years | NA | 20.30 | NA |
Financials
Company | Industry | |
---|---|---|
Price/Earnings (TTM) | NA | -2.18 |
Price/Book (MRQ) | 2.81 | 2.14 |
Price/Cash Flow (MRFY) | NA | 15.07 |
Dividend Yield | 0.00% | 0.00% |
Net Profit Margin (TTM) | -2,385.57% | -15.18% |
Return on Equity (TTM) | -29.55% | -19.32% |
Debt to Equity (MRQ) | 0.00 | 1.82 |
MRQ = Most Recent Quarter
TTM = Trailing Twelve Months
MRFY = Most Recent Fiscal Year
Note: Company and S&P 500 ratios relating to share price calculated daily; all others calculated weekly or in accordance with company earnings announcement. Industry medians calculated weekly.